Unity Biotechnology(UBX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 • In January, the Company published new research in Nature Medicine, "Therapeutics targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results" discussing the potential of UBX1325 to target senescence cells and thereby leading to long-lasting, disease-modifying intervention for DME • UBX1325 16-week safety and efficacy data from the Phase 2b ASPIRE DME study expected in the fourth quarter of 2024 • UBX1325 24-week safety and efficacy data from the Phase 2b ...